<?xml version="1.0" encoding="UTF-8"?>
<!--Generated by the Simple XML Sitemap Drupal module: https://drupal.org/project/simple_sitemap.-->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
 <url>
  <loc>http://www.sarepta.com/</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/"/>
  <lastmod>2024-09-25T18:48:08+00:00</lastmod>
  <changefreq>daily</changefreq>
  <priority>1.0</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/how-sarepta-infused-its-corporate-brand-urgency-and-optimism-behalf-patients</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/how-sarepta-infused-its-corporate-brand-urgency-and-optimism-behalf-patients"/>
  <lastmod>2023-04-26T16:48:43+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/whats-name-lot-limb-girdle-muscular-dystrophy-community</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/whats-name-lot-limb-girdle-muscular-dystrophy-community"/>
  <lastmod>2022-12-19T15:01:42+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/advocacy-community-unites-support-families</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/advocacy-community-unites-support-families"/>
  <lastmod>2023-04-26T16:48:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/art-science-how-one-sarepta-scientist-brings-arts-lab</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/art-science-how-one-sarepta-scientist-brings-arts-lab"/>
  <lastmod>2023-04-26T16:48:18+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/patiently-waiting</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/patiently-waiting"/>
  <lastmod>2023-04-26T16:49:59+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/expanding-access-newborn-screening-those-rare-diseases</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/expanding-access-newborn-screening-those-rare-diseases"/>
  <lastmod>2023-04-26T16:48:05+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/welcome-gt-faq</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/welcome-gt-faq"/>
  <lastmod>2022-12-19T15:03:43+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/how-collaboration-lab-led-seat-table-sareptas-gene-editing-innovation-center</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/how-collaboration-lab-led-seat-table-sareptas-gene-editing-innovation-center"/>
  <lastmod>2022-12-19T15:03:14+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/measurements-used-clinical-trials-duchenne-muscular-dystrophy-overview</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/measurements-used-clinical-trials-duchenne-muscular-dystrophy-overview"/>
  <lastmod>2023-04-26T16:47:37+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/seroprevalence-what-patients-should-know-about-pre-existing-antibodies-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/seroprevalence-what-patients-should-know-about-pre-existing-antibodies-gene-therapy"/>
  <lastmod>2022-12-19T15:05:39+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/patient-registries-catalyst-developing-new-therapies-rare-diseases</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/patient-registries-catalyst-developing-new-therapies-rare-diseases"/>
  <lastmod>2022-12-19T15:05:25+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/conversation-cfo-ian-estepan-recipient-2022-cfo-year-award-boston-business-journal</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/conversation-cfo-ian-estepan-recipient-2022-cfo-year-award-boston-business-journal"/>
  <lastmod>2023-04-26T16:46:32+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/pride-proud-what-belonging-feels-and-why-representation-matters</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/pride-proud-what-belonging-feels-and-why-representation-matters"/>
  <lastmod>2023-04-26T16:46:09+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/whatd-you-do-summer-our-summer-interns-share-lessons-learned</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/whatd-you-do-summer-our-summer-interns-share-lessons-learned"/>
  <lastmod>2022-12-19T15:02:14+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/meaningful-measure-understanding-nsaa-important-duchenne-functional-assessment-tool</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/meaningful-measure-understanding-nsaa-important-duchenne-functional-assessment-tool"/>
  <lastmod>2022-12-19T15:02:29+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/understanding-external-controls-and-their-importance-clinical-trials-rare-diseases</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/understanding-external-controls-and-their-importance-clinical-trials-rare-diseases"/>
  <lastmod>2022-12-19T15:02:44+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/dragging-tomorrow-today-meet-rachael-potter-phd</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/dragging-tomorrow-today-meet-rachael-potter-phd"/>
  <lastmod>2022-12-19T15:02:57+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/ensuring-safety-clinical-trial-participants-meet-eddie-darton-md</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/ensuring-safety-clinical-trial-participants-meet-eddie-darton-md"/>
  <lastmod>2023-04-26T16:47:21+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/creating-pathways-lgmd-genetic-diagnosis-spotlight-lgmd-grant-award-recipient</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/creating-pathways-lgmd-genetic-diagnosis-spotlight-lgmd-grant-award-recipient"/>
  <lastmod>2023-01-17T23:04:22+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/passion-patients-influential-mentor-and-change-plans-meet-danielle-griffin</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/passion-patients-influential-mentor-and-change-plans-meet-danielle-griffin"/>
  <lastmod>2024-09-09T17:32:20+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/why-are-steroids-used-gene-therapy-neuromuscular-disease</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/why-are-steroids-used-gene-therapy-neuromuscular-disease"/>
  <lastmod>2023-05-25T22:09:54+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/seeing-hope-genetic-medicines-frontier-meet-stefanie-mason-md</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/seeing-hope-genetic-medicines-frontier-meet-stefanie-mason-md"/>
  <lastmod>2023-05-09T14:46:50+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/whats-dose-gene-therapy-dosing-explained-video</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/whats-dose-gene-therapy-dosing-explained-video"/>
  <lastmod>2023-07-10T15:58:06+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/tale-two-interns-meet-kate-katherine-rare-disease-advocates-and-members-sareptas-patient</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/tale-two-interns-meet-kate-katherine-rare-disease-advocates-and-members-sareptas-patient"/>
  <lastmod>2023-07-25T21:55:04+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/guardians-last-mile-ensuring-smooth-delivery-and-seamless-patient-experience</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/guardians-last-mile-ensuring-smooth-delivery-and-seamless-patient-experience"/>
  <lastmod>2023-09-14T13:25:51+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/when-time-muscle-one-dad-shares-his-story-advocate-duchenne-newborn-screening</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/when-time-muscle-one-dad-shares-his-story-advocate-duchenne-newborn-screening"/>
  <lastmod>2024-03-13T20:43:53+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/continuing-family-legacy-meet-sarepta-colleague-and-duchenne-advocate-shawn-marlow</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/continuing-family-legacy-meet-sarepta-colleague-and-duchenne-advocate-shawn-marlow"/>
  <lastmod>2023-10-02T19:18:40+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/journey-better-understanding-lgmd-qa-early-findings-new-natural-history-study</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/journey-better-understanding-lgmd-qa-early-findings-new-natural-history-study"/>
  <lastmod>2024-05-20T17:25:44+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/awards-recognitions-sarepta-recognized-innovation-and-industry-leadership</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/awards-recognitions-sarepta-recognized-innovation-and-industry-leadership"/>
  <lastmod>2025-01-08T17:19:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/wearable-devices-and-future-rare-disease-clinical-trials-landrys-story</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/wearable-devices-and-future-rare-disease-clinical-trials-landrys-story"/>
  <lastmod>2024-11-19T16:59:34+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/navy-veteran-lifelong-learner-dedicated-duchenne-nurse-educator-meet-john-crane</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/navy-veteran-lifelong-learner-dedicated-duchenne-nurse-educator-meet-john-crane"/>
  <lastmod>2024-05-06T14:34:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom/roots-innovation-science-fairs-leading-edge-precision-genetic-medicine</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom/roots-innovation-science-fairs-leading-edge-precision-genetic-medicine"/>
  <lastmod>2024-12-02T22:02:03+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/disease-areas</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/disease-areas"/>
  <lastmod>2023-03-27T18:53:58+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science"/>
  <lastmod>2023-03-27T19:01:53+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/products-pipeline</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/products-pipeline"/>
  <lastmod>2023-06-23T21:45:07+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us"/>
  <lastmod>2020-02-24T19:53:33+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/join-us</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/join-us"/>
  <lastmod>2024-02-21T00:06:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/newsroom</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/newsroom"/>
  <lastmod>2022-12-16T20:06:14+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sareptassist</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sareptassist"/>
  <xhtml:link rel="alternate" hreflang="es" href="http://www.sarepta.com/es/sareptassist"/>
  <lastmod>2023-07-18T14:22:59+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/es/sareptassist</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sareptassist"/>
  <xhtml:link rel="alternate" hreflang="es" href="http://www.sarepta.com/es/sareptassist"/>
  <lastmod>2023-07-18T14:22:59+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/node/36</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/node/36"/>
  <lastmod>2024-09-25T18:48:08+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/testing-three-column-cards</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/testing-three-column-cards"/>
  <lastmod>2022-07-26T12:16:36+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/patient-affairs</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/patient-affairs"/>
  <lastmod>2025-02-13T18:49:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/disease-areas/duchenne-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/disease-areas/duchenne-muscular-dystrophy"/>
  <lastmod>2023-06-23T19:52:54+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/disease-areas/limb-girdle-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/disease-areas/limb-girdle-muscular-dystrophy"/>
  <lastmod>2023-03-28T22:32:17+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science/gene-editing</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science/gene-editing"/>
  <lastmod>2023-03-28T18:47:39+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science/gene-therapy-engine</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science/gene-therapy-engine"/>
  <lastmod>2023-06-23T20:14:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science/manufacturing</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science/manufacturing"/>
  <lastmod>2023-06-27T13:34:32+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science/strategic-partners</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science/strategic-partners"/>
  <lastmod>2024-09-25T18:39:47+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science/rna-platform</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science/rna-platform"/>
  <lastmod>2024-09-25T18:43:37+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/products-pipeline/products</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/products-pipeline/products"/>
  <lastmod>2023-11-29T19:21:20+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/products-pipeline/clinical-trials</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/products-pipeline/clinical-trials"/>
  <lastmod>2023-03-28T18:51:53+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/products-pipeline/treatment-access</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/products-pipeline/treatment-access"/>
  <lastmod>2025-02-04T18:02:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/leadership</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/leadership"/>
  <lastmod>2025-03-06T17:12:21+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/contact-us</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/contact-us"/>
  <lastmod>2021-09-15T19:16:07+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/terms-use</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/terms-use"/>
  <lastmod>2024-01-25T20:19:13+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/disease-areas/charcot-marie-tooth-disease</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/disease-areas/charcot-marie-tooth-disease"/>
  <lastmod>2020-02-24T19:41:07+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/products-pipeline/pipeline</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/products-pipeline/pipeline"/>
  <lastmod>2024-06-28T17:03:17+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/grants-giving</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/grants-giving"/>
  <lastmod>2025-03-10T19:00:36+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/404</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/404"/>
  <lastmod>2020-01-07T15:47:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/feedback</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/feedback"/>
  <lastmod>2020-05-22T15:07:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/global-locations</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/global-locations"/>
  <lastmod>2022-06-07T13:24:48+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/app-terms</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/app-terms"/>
  <lastmod>2020-01-14T13:01:13+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/thank-you</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/thank-you"/>
  <lastmod>2020-01-14T13:03:22+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-guidelines</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-guidelines"/>
  <lastmod>2023-02-07T15:25:00+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/upload</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/upload"/>
  <lastmod>2020-01-14T13:06:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/events</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/events"/>
  <xhtml:link rel="alternate" hreflang="es" href="http://www.sarepta.com/es/evento"/>
  <lastmod>2020-01-14T13:57:04+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/es/evento</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/events"/>
  <xhtml:link rel="alternate" hreflang="es" href="http://www.sarepta.com/es/evento"/>
  <lastmod>2020-01-14T13:57:04+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/peer</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/peer"/>
  <lastmod>2020-01-14T17:59:15+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/peer-confirmation</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/peer-confirmation"/>
  <lastmod>2020-03-09T15:41:42+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/grants-giving/route79</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/grants-giving/route79"/>
  <lastmod>2025-02-27T23:14:06+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/terms-embed</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/terms-embed"/>
  <lastmod>2021-03-10T22:00:53+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/privacy-embed</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/privacy-embed"/>
  <lastmod>2021-03-10T21:59:37+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/privacy-policy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/privacy-policy"/>
  <lastmod>2024-01-25T20:16:58+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-update-covid-19</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-update-covid-19"/>
  <lastmod>2020-12-18T16:55:16+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sareptas-response-covid-19</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sareptas-response-covid-19"/>
  <lastmod>2020-04-01T16:41:42+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/about-us/corporate-responsibility</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/about-us/corporate-responsibility"/>
  <lastmod>2024-05-08T14:51:22+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/eu-us-swiss-us-and-uk-extension-eu-us-data-privacy-framework-privacy-policy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/eu-us-swiss-us-and-uk-extension-eu-us-data-privacy-framework-privacy-policy"/>
  <lastmod>2024-08-13T16:25:54+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/rarelessons</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/rarelessons"/>
  <lastmod>2021-02-01T15:14:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sareptassist-virtual-event</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sareptassist-virtual-event"/>
  <lastmod>2020-09-17T16:27:22+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/recruiting-fraud</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/recruiting-fraud"/>
  <lastmod>2020-12-07T19:08:55+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/GTFAQ</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/GTFAQ"/>
  <lastmod>2021-04-26T15:54:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-momentum-study-srp-5051-201-update</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-momentum-study-srp-5051-201-update"/>
  <lastmod>2022-01-05T15:02:41+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-covid-19-vaccination-and-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-covid-19-vaccination-and-gene-therapy"/>
  <lastmod>2022-01-05T16:32:12+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-srp-9001-clinical-trial-updates</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-srp-9001-clinical-trial-updates"/>
  <lastmod>2022-01-05T16:32:56+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-srp-9001-study-103-clinical-trial-update</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-srp-9001-study-103-clinical-trial-update"/>
  <lastmod>2022-01-05T16:37:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-limb-girdle-facebook-live-event</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-limb-girdle-facebook-live-event"/>
  <lastmod>2022-01-05T16:40:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-embark-study-srp-9001-301-enrollment-update</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-embark-study-srp-9001-301-enrollment-update"/>
  <lastmod>2022-09-13T13:06:39+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-q1-update-lgmd-programs-development</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-q1-update-lgmd-programs-development"/>
  <lastmod>2022-03-03T15:46:34+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/addressing-your-questions-about-covid-19-vaccination-and-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/addressing-your-questions-about-covid-19-vaccination-and-gene-therapy"/>
  <lastmod>2022-03-23T14:19:44+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-lgmd-2br2-community</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-lgmd-2br2-community"/>
  <lastmod>2022-05-02T17:00:10+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/lgmd-grant-award-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/lgmd-grant-award-program"/>
  <lastmod>2024-03-19T00:06:42+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-sarepta-duchenne-pipeline</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-sarepta-duchenne-pipeline"/>
  <lastmod>2022-06-09T00:17:53+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-momentum-trial</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-momentum-trial"/>
  <lastmod>2022-09-06T13:50:19+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-intent-submit-accelerated-approval-biologics-license-application-srp-9001</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-intent-submit-accelerated-approval-biologics-license-application-srp-9001"/>
  <lastmod>2022-07-29T11:27:48+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-bulletin-bla-accepted-filing-priority-review</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-bulletin-bla-accepted-filing-priority-review"/>
  <lastmod>2022-11-28T16:47:03+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-community-update-lgmd-programs-development</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-community-update-lgmd-programs-development"/>
  <lastmod>2023-02-17T13:56:37+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/notice-cookies</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/notice-cookies"/>
  <lastmod>2023-03-14T14:32:41+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-srp-9001-advisory-committee-meeting-will-be-held</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-srp-9001-advisory-committee-meeting-will-be-held"/>
  <lastmod>2023-03-16T20:27:55+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-srp-9001-advisory-committee-date-announced</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-srp-9001-advisory-committee-date-announced"/>
  <lastmod>2023-04-10T13:40:12+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-srp-9001-update-regulatory-review</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-srp-9001-update-regulatory-review"/>
  <lastmod>2023-05-24T12:24:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/srp-9001-303-envision-study-enrollment-us</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/srp-9001-303-envision-study-enrollment-us"/>
  <lastmod>2023-06-08T16:49:15+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-embark-part-1-topline-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-embark-part-1-topline-results"/>
  <lastmod>2023-10-30T20:11:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/science/investigator-initiated-studies</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/science/investigator-initiated-studies"/>
  <lastmod>2024-08-28T21:07:00+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-update-srp-5051-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-update-srp-5051-program"/>
  <lastmod>2024-11-06T21:10:06+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/community-letter-update-lgmd-programs-srp-9003-srp-9004-srp-9005</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/community-letter-update-lgmd-programs-srp-9003-srp-9004-srp-9005"/>
  <lastmod>2024-12-19T16:13:49+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2019-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2019-financial-results-and-recent-corporate"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-0</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-0"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-goldman-sachs-40th-annual-global-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-goldman-sachs-40th-annual-global-healthcare-conference"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-statement-icer-draft-evidence-report-treatments-duchenne-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-statement-icer-draft-evidence-report-treatments-duchenne-muscular-dystrophy"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2019-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2019-financial-results-and-recent-corporate"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-announces-agreement-nationwide-childrens-hospital-rights-its-gene-therapy-program-treat</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-announces-agreement-nationwide-childrens-hospital-rights-its-gene-therapy-program-treat"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2019-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2019-financial-results-and-recent-corporate"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2"/>
  <lastmod>2019-08-06T22:34:28+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-appoints-renowned-biotech-executive-john-c-martin-its-board-directors</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-appoints-renowned-biotech-executive-john-c-martin-its-board-directors"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-38th-annual-jp-morgan-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-38th-annual-jp-morgan-healthcare-conference"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-partnership-roche-territories-outside-united-states-its</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-partnership-roche-territories-outside-united-states-its"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-250-million-non-dilutive-senior-secured-loan-financing</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-250-million-non-dilutive-senior-secured-loan-financing"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-vyondys-53tm-golodirsen-injection-treatment-duchenne</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-vyondys-53tm-golodirsen-injection-treatment-duchenne"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-and-stridebio-announce-multi-target-strategic-collaboration-advance-novel-gene-therapies</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-and-stridebio-announce-multi-target-strategic-collaboration-advance-novel-gene-therapies"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2019-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2019-financial-results-and-recent-corporate"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-credit-suisse-28th-annual-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-credit-suisse-28th-annual-healthcare-conference"/>
  <lastmod>2020-01-22T21:41:26+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-5"/>
  <lastmod>2020-02-10T15:25:11+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2019-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2019-financial-results-and-recent"/>
  <lastmod>2020-02-24T15:57:47+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6"/>
  <lastmod>2020-02-24T15:57:47+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-38th-annual-jp-morgan-healthcare-conference-0</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-38th-annual-jp-morgan-healthcare-conference-0"/>
  <lastmod>2020-02-24T15:57:47+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-7"/>
  <lastmod>2020-03-02T18:13:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-year-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-year-route-79-duchenne-scholarship-program"/>
  <lastmod>2020-03-02T18:13:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-recent"/>
  <lastmod>2020-03-02T18:13:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8"/>
  <lastmod>2020-04-01T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-research-agreement-us-department-defense-evaluate-multiple</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-research-agreement-us-department-defense-evaluate-multiple"/>
  <lastmod>2020-04-28T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2020-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2020-financial-results-and-recent-corporate"/>
  <lastmod>2020-04-29T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-9</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-9"/>
  <lastmod>2020-05-01T02:00:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2020-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2020-financial-results-and-recent-corporate"/>
  <lastmod>2020-05-07T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-and-dyno-therapeutics-announce-agreement-develop-next-generation-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-and-dyno-therapeutics-announce-agreement-develop-next-generation-gene-therapy"/>
  <lastmod>2020-05-11T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-2020-rbc-capital-markets-virtual-global-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-2020-rbc-capital-markets-virtual-global-healthcare-conference"/>
  <lastmod>2020-05-13T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-10</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-10"/>
  <lastmod>2020-05-30T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences"/>
  <lastmod>2020-06-03T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-srp-9003-gene-therapy-trial-treat-limb-girdle-muscular</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-srp-9003-gene-therapy-trial-treat-limb-girdle-muscular"/>
  <lastmod>2020-06-06T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-positive-expression-and-functional-data-srp-9003-gene-therapy-trial</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-positive-expression-and-functional-data-srp-9003-gene-therapy-trial"/>
  <lastmod>2020-06-08T14:00:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-positive-safety-and-efficacy-data-srp-9001-micro-dystrophin-gene</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-positive-safety-and-efficacy-data-srp-9001-micro-dystrophin-gene"/>
  <lastmod>2020-06-16T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-and-selecta-biosciences-enter-research-license-and-option-agreement-selectas</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-and-selecta-biosciences-enter-research-license-and-option-agreement-selectas"/>
  <lastmod>2020-06-18T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-and-codiak-biosciences-collaborate-research-and-develop-exosome-based</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-and-codiak-biosciences-collaborate-research-and-develop-exosome-based"/>
  <lastmod>2020-06-22T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-completes-submission-new-drug-application-seeking-approval-casimersen-srp-4045</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-completes-submission-new-drug-application-seeking-approval-casimersen-srp-4045"/>
  <lastmod>2020-06-26T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-retirement-sandy-mahatme-chief-financial-officer-and-chief-business</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-retirement-sandy-mahatme-chief-financial-officer-and-chief-business"/>
  <lastmod>2020-06-30T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-11</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-11"/>
  <lastmod>2020-07-01T02:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-signs-agreement-hansa-biopharma-imlifidase</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-signs-agreement-hansa-biopharma-imlifidase"/>
  <lastmod>2020-07-02T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-launches-rare-lessons-program-promote-greater-diversity-and-inclusion</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-launches-rare-lessons-program-promote-greater-diversity-and-inclusion"/>
  <lastmod>2020-07-15T14:00:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-receives-fast-track-designation-srp-9001-micro-dystrophin-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-receives-fast-track-designation-srp-9001-micro-dystrophin-gene-therapy"/>
  <lastmod>2020-07-24T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2020-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2020-financial-results-and-recent-corporate"/>
  <lastmod>2020-07-29T14:00:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-12"/>
  <lastmod>2020-08-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2020-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2020-financial-results-and-recent-corporate"/>
  <lastmod>2020-08-05T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-and-university-florida-announce-collaboration-accelerate-discovery-and</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-and-university-florida-announce-collaboration-accelerate-discovery-and"/>
  <lastmod>2020-08-20T13:17:16+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fda-acceptance-casimersen-srp-4045-new-drug-application-patients</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fda-acceptance-casimersen-srp-4045-new-drug-application-patients"/>
  <lastmod>2020-08-25T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-13"/>
  <lastmod>2020-09-01T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-0</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-0"/>
  <lastmod>2020-09-04T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-provides-program-update-srp-9001-its-investigational-gene-therapy-treatment</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-provides-program-update-srp-9001-its-investigational-gene-therapy-treatment"/>
  <lastmod>2020-09-10T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/long-term-functional-data-sarepta-therapeutics-most-advanced-gene-therapy-programs-be-presented</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/long-term-functional-data-sarepta-therapeutics-most-advanced-gene-therapy-programs-be-presented"/>
  <lastmod>2020-09-14T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program"/>
  <lastmod>2020-09-15T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-reports-sustained-functional-improvement-two-years-after-treatment-srp-9001</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-reports-sustained-functional-improvement-two-years-after-treatment-srp-9001"/>
  <lastmod>2020-09-28T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9003-treatment-limb-girdle-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9003-treatment-limb-girdle-muscular-dystrophy"/>
  <lastmod>2020-09-28T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-14</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-14"/>
  <lastmod>2020-10-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/gene-therapy-company-aavantibio-launches-107-million-series-financing-perceptive-advisors-bain</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/gene-therapy-company-aavantibio-launches-107-million-series-financing-perceptive-advisors-bain"/>
  <lastmod>2020-10-22T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2020-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2020-financial-results-and-recent-corporate"/>
  <lastmod>2020-10-29T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-29th-annual-credit-suisse-virtual-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-29th-annual-credit-suisse-virtual-healthcare-conference"/>
  <lastmod>2020-11-03T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2020-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2020-financial-results-and-recent-corporate"/>
  <lastmod>2020-11-06T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-commence-dosing-next-study-commercial-process-material-srp-9001-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-commence-dosing-next-study-commercial-process-material-srp-9001-gene-therapy"/>
  <lastmod>2020-11-06T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-named-one-boston-globes-top-places-work-2020</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-named-one-boston-globes-top-places-work-2020"/>
  <lastmod>2020-11-20T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-evercore-isi-3rd-annual-healthconx-virtual-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-evercore-isi-3rd-annual-healthconx-virtual-conference"/>
  <lastmod>2020-11-25T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-15</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-15"/>
  <lastmod>2020-12-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-srp-5051-its-investigational-ppmo-treatment-duchenne</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-srp-5051-its-investigational-ppmo-treatment-duchenne"/>
  <lastmod>2020-12-05T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-positive-clinical-results-momentum-phase-2-clinical-trial-srp-5051</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-positive-clinical-results-momentum-phase-2-clinical-trial-srp-5051"/>
  <lastmod>2020-12-07T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-executive-management-changes</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-executive-management-changes"/>
  <lastmod>2020-12-14T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16"/>
  <lastmod>2021-01-01T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-top-line-results-part-1-study-102-evaluating-srp-9001-its</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-top-line-results-part-1-study-102-evaluating-srp-9001-its"/>
  <lastmod>2021-01-08T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-39th-annual-jp-morgan-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-39th-annual-jp-morgan-healthcare-conference"/>
  <lastmod>2021-01-08T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-and-genevant-sciences-announce-research-collaboration-lipid-nanoparticle-based</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-and-genevant-sciences-announce-research-collaboration-lipid-nanoparticle-based"/>
  <lastmod>2021-01-13T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-17</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-17"/>
  <lastmod>2021-01-30T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-winners-rare-lessons-lesson-planning-competition</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-winners-rare-lessons-lesson-planning-competition"/>
  <lastmod>2021-02-05T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2020-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2020-financial-results-and-recent"/>
  <lastmod>2021-02-22T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-1</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-1"/>
  <lastmod>2021-02-25T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-amondys-45tm-casimersen-injection-treatment-duchenne</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-amondys-45tm-casimersen-injection-treatment-duchenne"/>
  <lastmod>2021-02-25T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-18</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-18"/>
  <lastmod>2021-02-27T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-recent"/>
  <lastmod>2021-03-02T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-results-its-gene-therapy-and-rna-platforms-2021-annual-mda-clinical</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-results-its-gene-therapy-and-rna-platforms-2021-annual-mda-clinical"/>
  <lastmod>2021-03-15T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9003-treatment-limb-girdle-muscular-0</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9003-treatment-limb-girdle-muscular-0"/>
  <lastmod>2021-03-19T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-year-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-year-route-79-duchenne-scholarship-program"/>
  <lastmod>2021-03-23T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-recommends-stockholders-reject-below-market-mini-tender-offer-trc-capital-investment</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-recommends-stockholders-reject-below-market-mini-tender-offer-trc-capital-investment"/>
  <lastmod>2021-04-26T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-statement-april-26-2021-icer-commentary-regarding-accelerated-approval-pathway</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-statement-april-26-2021-icer-commentary-regarding-accelerated-approval-pathway"/>
  <lastmod>2021-04-27T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2021-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2021-financial-results-and-recent-corporate"/>
  <lastmod>2021-04-28T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-30-mgkg-arm-momentum-study-srp-5051-its-investigational</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-share-clinical-update-30-mgkg-arm-momentum-study-srp-5051-its-investigational"/>
  <lastmod>2021-04-30T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-19</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-19"/>
  <lastmod>2021-05-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-reports-positive-clinical-results-phase-2-momentum-study-srp-5051-patients</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-reports-positive-clinical-results-phase-2-momentum-study-srp-5051-patients"/>
  <lastmod>2021-05-03T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-2</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-2"/>
  <lastmod>2021-05-05T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2021-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2021-financial-results-and-recent-corporate"/>
  <lastmod>2021-05-05T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-share-expression-and-safety-results-study-103-endeavor-evaluating-srp-9001-its</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-share-expression-and-safety-results-study-103-endeavor-evaluating-srp-9001-its"/>
  <lastmod>2021-05-17T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-treatment-duchenne-muscular-dystrophy-srp-9001</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-treatment-duchenne-muscular-dystrophy-srp-9001"/>
  <lastmod>2021-05-18T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-20</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-20"/>
  <lastmod>2021-05-29T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-3</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-3"/>
  <lastmod>2021-06-04T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-21</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-21"/>
  <lastmod>2021-07-01T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2021-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2021-financial-results-and-recent-corporate"/>
  <lastmod>2021-07-28T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-22</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-22"/>
  <lastmod>2021-07-31T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-executes-licensing-agreement-gene-therapy-program-nationwide-childrens</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-executes-licensing-agreement-gene-therapy-program-nationwide-childrens"/>
  <lastmod>2021-08-04T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2021-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2021-financial-results-and-recent-corporate"/>
  <lastmod>2021-08-04T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23"/>
  <lastmod>2021-09-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-0</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-0"/>
  <lastmod>2021-09-07T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-4</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-4"/>
  <lastmod>2021-09-08T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-showcase-data-its-gene-therapy-and-rna-platforms-world-muscle-society-2021</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-showcase-data-its-gene-therapy-and-rna-platforms-world-muscle-society-2021"/>
  <lastmod>2021-09-14T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-initiate-part-b-momentum-study-srp-5051-patients-duchenne-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-initiate-part-b-momentum-study-srp-5051-patients-duchenne-muscular-dystrophy"/>
  <lastmod>2021-09-27T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-24"/>
  <lastmod>2021-10-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-initiation-embark-global-pivotal-study-srp-9001-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-initiation-embark-global-pivotal-study-srp-9001-gene-therapy"/>
  <lastmod>2021-10-04T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-opens-genetic-therapies-center-excellence-columbus-ohio</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-opens-genetic-therapies-center-excellence-columbus-ohio"/>
  <lastmod>2021-10-05T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-srp-9001-shows-sustained-functional-improvements-multiple-studies-patients</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-srp-9001-shows-sustained-functional-improvements-multiple-studies-patients"/>
  <lastmod>2021-10-11T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-preliminary-financial-results-third-quarter-ended-september-30-2021</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-preliminary-financial-results-third-quarter-ended-september-30-2021"/>
  <lastmod>2021-10-13T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-proposed-500000000-public-offering-common-stock</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-proposed-500000000-public-offering-common-stock"/>
  <lastmod>2021-10-12T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-pricing-500-million-public-offering-common-stock</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-pricing-500-million-public-offering-common-stock"/>
  <lastmod>2021-10-14T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2021-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2021-financial-results-and-recent-corporate"/>
  <lastmod>2021-10-27T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-25</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-25"/>
  <lastmod>2021-10-30T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-5</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-5"/>
  <lastmod>2021-11-03T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2021-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2021-financial-results-and-recent-corporate"/>
  <lastmod>2021-11-03T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-names-louise-rodino-klapac-phd-head-research-and-development</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-names-louise-rodino-klapac-phd-head-research-and-development"/>
  <lastmod>2021-11-29T23:02:22+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-appoints-stephen-l-mayo-phd-its-board-directors</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-appoints-stephen-l-mayo-phd-its-board-directors"/>
  <lastmod>2021-11-29T23:02:22+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-26</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-26"/>
  <lastmod>2021-12-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-27</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-27"/>
  <lastmod>2022-01-06T14:47:05+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-40th-annual-jp-morgan-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-40th-annual-jp-morgan-healthcare-conference"/>
  <lastmod>2022-01-06T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-gene-therapy-srp-9001-shows-statistically-significant-functional-improvements</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-gene-therapy-srp-9001-shows-statistically-significant-functional-improvements"/>
  <lastmod>2022-01-10T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-28</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-28"/>
  <lastmod>2022-02-01T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-and-genedit-share-progress-research-collaboration-and-announce-agreement</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-and-genedit-share-progress-research-collaboration-and-announce-agreement"/>
  <lastmod>2022-02-01T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2021-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2021-financial-results-and-recent"/>
  <lastmod>2022-02-22T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-launch-sareptacircle-highlight-experiences-individuals-and-families</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-launch-sareptacircle-highlight-experiences-individuals-and-families"/>
  <lastmod>2022-02-23T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-el-lanzamiento-de-sareptacircle-para-destacar-las-experiencias-de</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-el-lanzamiento-de-sareptacircle-para-destacar-las-experiencias-de"/>
  <lastmod>2022-02-23T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-29</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-29"/>
  <lastmod>2022-03-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-recent"/>
  <lastmod>2022-03-02T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-6</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-6"/>
  <lastmod>2022-03-03T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fifth-year-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fifth-year-route-79-duchenne-scholarship-program"/>
  <lastmod>2022-03-08T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-quinto-ano-de-route-79-el-programa-de-becas-duchenne</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-quinto-ano-de-route-79-el-programa-de-becas-duchenne"/>
  <lastmod>2022-03-08T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-30</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-30"/>
  <lastmod>2022-04-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2022-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2022-financial-results-and-recent-corporate"/>
  <lastmod>2022-04-27T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-31"/>
  <lastmod>2022-04-30T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-bofa-securities-2022-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-bofa-securities-2022-healthcare-conference"/>
  <lastmod>2022-05-04T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2022-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2022-financial-results-and-recent-corporate"/>
  <lastmod>2022-05-04T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-launches-inaugural-lgmd-grant-award-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-launches-inaugural-lgmd-grant-award-program"/>
  <lastmod>2022-05-05T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-lanza-el-programa-inaugural-de-concesion-de-subvenciones-para-la-lgmd</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-lanza-el-programa-inaugural-de-concesion-de-subvenciones-para-la-lgmd"/>
  <lastmod>2022-05-10T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-32</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-32"/>
  <lastmod>2022-06-01T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-goldman-sachs-43rd-annual-global-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-goldman-sachs-43rd-annual-global-healthcare-conference"/>
  <lastmod>2022-06-02T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-appoints-michael-chambers-and-kathryn-boor-phd-its-board-directors</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-appoints-michael-chambers-and-kathryn-boor-phd-its-board-directors"/>
  <lastmod>2022-06-02T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-provides-update-srp-5051-treatment-duchenne-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-provides-update-srp-5051-treatment-duchenne-muscular-dystrophy"/>
  <lastmod>2022-06-23T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-33</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-33"/>
  <lastmod>2022-07-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-share-new-clinical-data-and-integrated-analysis-srp-9001-its-investigational</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-share-new-clinical-data-and-integrated-analysis-srp-9001-its-investigational"/>
  <lastmod>2022-07-05T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9001-duchenne-muscular-dystrophy-demonstrates</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-investigational-gene-therapy-srp-9001-duchenne-muscular-dystrophy-demonstrates"/>
  <lastmod>2022-07-06T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2022-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2022-financial-results-and-recent-corporate"/>
  <lastmod>2022-07-26T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-intent-submit-accelerated-approval-biologics-license-application-its</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-intent-submit-accelerated-approval-biologics-license-application-its"/>
  <lastmod>2022-07-29T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-34</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-34"/>
  <lastmod>2022-07-30T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2022-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2022-financial-results-and-recent-corporate"/>
  <lastmod>2022-08-02T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-progress-myoaav-program-and-exclusive-licensing-agreement-broad</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-progress-myoaav-program-and-exclusive-licensing-agreement-broad"/>
  <lastmod>2022-08-08T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35"/>
  <lastmod>2022-09-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold-srp-5051-treatment-duchenne</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold-srp-5051-treatment-duchenne"/>
  <lastmod>2022-09-06T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-20th-annual-global-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-20th-annual-global-healthcare-conference"/>
  <lastmod>2022-09-06T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-2022-2023-academic</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-route-79-duchenne-scholarship-program-2022-2023-academic"/>
  <lastmod>2022-09-07T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-route-79-el-programa-de-becas-de-duchenne-para-el</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-route-79-el-programa-de-becas-de-duchenne-para-el"/>
  <lastmod>2022-09-08T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-proposed-offering-10-billion-convertible-senior-notes-due-2027</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-proposed-offering-10-billion-convertible-senior-notes-due-2027"/>
  <lastmod>2022-09-13T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-prices-10-billion-convertible-senior-notes-due-2027</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-prices-10-billion-convertible-senior-notes-due-2027"/>
  <lastmod>2022-09-14T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-submits-biologics-license-application-srp-9001-treatment-ambulant-patients</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-submits-biologics-license-application-srp-9001-treatment-ambulant-patients"/>
  <lastmod>2022-09-29T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-36</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-36"/>
  <lastmod>2022-10-01T12:35:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-presents-new-data-its-gene-therapy-and-rna-platforms-world-muscle-society-2022</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-presents-new-data-its-gene-therapy-and-rna-platforms-world-muscle-society-2022"/>
  <lastmod>2022-10-07T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2022-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2022-financial-results"/>
  <lastmod>2022-10-26T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-inaugural-lgmd-grant-awards-program-supports-innovative</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-inaugural-lgmd-grant-awards-program-supports-innovative"/>
  <lastmod>2022-10-26T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-los-beneficiarios-de-la-entrega-inaugural-de-subvenciones-para-lgmd-el</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-los-beneficiarios-de-la-entrega-inaugural-de-subvenciones-para-lgmd-el"/>
  <lastmod>2022-10-26T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-37</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-37"/>
  <lastmod>2022-11-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2022-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2022-financial-results-and-recent-corporate"/>
  <lastmod>2022-11-02T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-evercore-isi-healthconx-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-evercore-isi-healthconx-conference"/>
  <lastmod>2022-11-23T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-us-fda-has-accepted-filing-and-granted-priority-review-biologics</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-us-fda-has-accepted-filing-and-granted-priority-review-biologics"/>
  <lastmod>2022-11-28T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-38</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-38"/>
  <lastmod>2022-12-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-39</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-39"/>
  <lastmod>2022-12-31T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-41st-annual-jp-morgan-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-41st-annual-jp-morgan-healthcare-conference"/>
  <lastmod>2023-01-03T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-and-catalent-expand-strategic-manufacturing-partnership-commercial-supply-agreement</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-and-catalent-expand-strategic-manufacturing-partnership-commercial-supply-agreement"/>
  <lastmod>2023-01-05T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2022-net-product-revenues</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2022-net-product-revenues"/>
  <lastmod>2023-01-09T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-40</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-40"/>
  <lastmod>2023-02-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-initiation-voyagene-clinical-study-srp-9003-treatment-limb-girdle</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-initiation-voyagene-clinical-study-srp-9003-treatment-limb-girdle"/>
  <lastmod>2023-02-17T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2022-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2022-financial-results"/>
  <lastmod>2023-02-21T20:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-6th-annual-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-6th-annual-route-79-duchenne-scholarship-program"/>
  <lastmod>2023-02-28T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-convocatoria-de-solicitudes-para-el-6o-route-79-anual-el-programa-de</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-convocatoria-de-solicitudes-para-el-6o-route-79-anual-el-programa-de"/>
  <lastmod>2023-02-28T20:30:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-41</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-41"/>
  <lastmod>2023-03-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-recent"/>
  <lastmod>2023-03-01T12:35:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-advisory-committee-meeting-will-be-held-srp-9001</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-advisory-committee-meeting-will-be-held-srp-9001"/>
  <lastmod>2023-03-16T21:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-42</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-42"/>
  <lastmod>2023-04-01T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-date-advisory-committee-meeting-srp-9001-will-be-may-12-2023</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-date-advisory-committee-meeting-srp-9001-will-be-may-12-2023"/>
  <lastmod>2023-04-10T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2023-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2023-financial-results"/>
  <lastmod>2023-04-25T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-43</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-43"/>
  <lastmod>2023-04-29T14:10:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2023-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2023-financial-results-and-recent-corporate"/>
  <lastmod>2023-05-02T21:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-positive-vote-us-fda-advisory-committee-meeting-srp-9001-gene</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-positive-vote-us-fda-advisory-committee-meeting-srp-9001-gene"/>
  <lastmod>2023-05-13T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-update-regulatory-review-srp-9001</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-update-regulatory-review-srp-9001"/>
  <lastmod>2023-05-24T12:54:41+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-44</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-44"/>
  <lastmod>2023-06-01T14:10:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene-therapy-treat-duchenne-muscular</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene-therapy-treat-duchenne-muscular"/>
  <lastmod>2023-06-22T18:09:10+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-45</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-45"/>
  <lastmod>2023-07-01T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-cowens-2nd-annual-rna-therapeutics-summit</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-cowens-2nd-annual-rna-therapeutics-summit"/>
  <lastmod>2023-07-03T14:10:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-sale-priority-review-voucher-102-million</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-sale-priority-review-voucher-102-million"/>
  <lastmod>2023-07-05T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2023-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2023-financial-results"/>
  <lastmod>2023-07-26T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-46</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-46"/>
  <lastmod>2023-08-01T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2023-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2023-financial-results-and-recent-corporate"/>
  <lastmod>2023-08-02T21:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/quest-diagnostics-granted-fda-breakthrough-designation-its-adeno-associated-virus-aav-test</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/quest-diagnostics-granted-fda-breakthrough-designation-its-adeno-associated-virus-aav-test"/>
  <lastmod>2023-08-30T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-47</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-47"/>
  <lastmod>2023-09-01T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-21st-annual-global-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-21st-annual-global-healthcare-conference"/>
  <lastmod>2023-09-05T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-6th-annual-route-79-duchenne-scholarship-program-2023</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-6th-annual-route-79-duchenne-scholarship-program-2023"/>
  <lastmod>2023-09-07T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-la-6a-edicion-anual-de-route-79-el-programa-de</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-la-6a-edicion-anual-de-route-79-el-programa-de"/>
  <lastmod>2023-09-07T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-48</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-48"/>
  <lastmod>2023-09-30T14:10:02+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2023-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2023-financial-results"/>
  <lastmod>2023-10-25T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-topline-results-embark-global-pivotal-study-elevidys-gene-therapy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-topline-results-embark-global-pivotal-study-elevidys-gene-therapy"/>
  <lastmod>2023-10-30T21:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-49</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-49"/>
  <lastmod>2023-11-01T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2023-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2023-financial-results-and-recent-corporate"/>
  <lastmod>2023-11-01T21:30:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-ubs-biopharma-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-ubs-biopharma-conference"/>
  <lastmod>2023-11-02T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-50</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-50"/>
  <lastmod>2023-12-01T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-submits-efficacy-supplement-expand-elevidys-label-include-duchenne-muscular</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-submits-efficacy-supplement-expand-elevidys-label-include-duchenne-muscular"/>
  <lastmod>2023-12-22T14:10:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-51</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-51"/>
  <lastmod>2023-12-30T14:10:34+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-42nd-annual-jp-morgan-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-42nd-annual-jp-morgan-healthcare-conference"/>
  <lastmod>2024-01-02T14:10:58+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2023-net-product-revenue</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2023-net-product-revenue"/>
  <lastmod>2024-01-08T21:30:47+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-initiates-screening-emergene-phase-3-clinical-study-srp-9003-treatment-limb</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-initiates-screening-emergene-phase-3-clinical-study-srp-9003-treatment-limb"/>
  <lastmod>2024-01-16T14:10:23+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-positive-data-part-b-momentum-phase-2-study-srp-5051-patients</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-positive-data-part-b-momentum-phase-2-study-srp-5051-patients"/>
  <lastmod>2024-01-29T14:10:41+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-52</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-52"/>
  <lastmod>2024-02-01T14:10:31+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-us-fda-acceptance-efficacy-supplement-expand-elevidys-indication</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-us-fda-acceptance-efficacy-supplement-expand-elevidys-indication"/>
  <lastmod>2024-02-16T14:11:55+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2023-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2023-financial-results"/>
  <lastmod>2024-02-21T14:12:33+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-recent"/>
  <lastmod>2024-02-28T21:31:19+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-7th-annual-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-7th-annual-route-79-duchenne-scholarship-program"/>
  <lastmod>2024-02-29T14:11:45+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-convocatoria-de-solicitudes-para-el-7o-route-79-anual-el-programa-de</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-convocatoria-de-solicitudes-para-el-7o-route-79-anual-el-programa-de"/>
  <lastmod>2024-02-29T21:34:00+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-53</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-53"/>
  <lastmod>2024-03-01T14:11:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-7</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-upcoming-investor-conferences-7"/>
  <lastmod>2024-03-04T14:11:23+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-la-convocatoria-de-solicitudes-para-el-programa-de-concesion-de</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-la-convocatoria-de-solicitudes-para-el-programa-de-concesion-de"/>
  <lastmod>2024-03-19T14:10:23+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-2024-lgmd-grant-award-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-2024-lgmd-grant-award-program"/>
  <lastmod>2024-03-19T14:10:23+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-54</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-54"/>
  <lastmod>2024-03-29T21:30:42+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2024-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-first-quarter-2024-financial-results"/>
  <lastmod>2024-04-24T14:10:37+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-55</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-55"/>
  <lastmod>2024-05-01T14:10:34+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2024-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-first-quarter-2024-financial-results-and-recent-corporate"/>
  <lastmod>2024-05-01T21:31:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/gene-therapy-pioneer-jerry-r-mendell-md-named-inaugural-time100-health-list-100-most-influential</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/gene-therapy-pioneer-jerry-r-mendell-md-named-inaugural-time100-health-list-100-most-influential"/>
  <lastmod>2024-05-03T14:10:25+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-56</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-56"/>
  <lastmod>2024-06-01T14:10:42+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys-duchenne-muscular-dystrophy</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys-duchenne-muscular-dystrophy"/>
  <lastmod>2024-06-20T21:31:13+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-57</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-57"/>
  <lastmod>2024-06-29T14:10:27+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2024-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-second-quarter-2024-financial-results"/>
  <lastmod>2024-07-29T14:10:47+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-58</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-58"/>
  <lastmod>2024-07-31T21:30:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2024-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-second-quarter-2024-financial-results-and-recent-corporate"/>
  <lastmod>2024-08-07T21:30:45+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-22nd-annual-global-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-morgan-stanley-22nd-annual-global-healthcare-conference"/>
  <lastmod>2024-08-30T14:10:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-59</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-59"/>
  <lastmod>2024-08-30T21:30:24+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-7th-annual-route-79-duchenne-scholarship-program-2024</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-7th-annual-route-79-duchenne-scholarship-program-2024"/>
  <lastmod>2024-09-05T14:10:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-la-7a-edicion-anual-de-route-79-el-programa-de</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-la-7a-edicion-anual-de-route-79-el-programa-de"/>
  <lastmod>2024-09-05T14:10:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-appoints-deirdre-connelly-its-board-directors</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-appoints-deirdre-connelly-its-board-directors"/>
  <lastmod>2024-09-16T14:10:46+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-new-data-its-neuromuscular-portfolio-2024-world-muscle-society</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-new-data-its-neuromuscular-portfolio-2024-world-muscle-society"/>
  <lastmod>2024-09-26T14:10:30+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-recipients-lgmd-grant-awards-2024-program-supports-early-genetic</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-recipients-lgmd-grant-awards-2024-program-supports-early-genetic"/>
  <lastmod>2024-09-30T14:10:36+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-las-subvenciones-de-2024-para-lgmd-el-programa</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-los-destinatarios-de-las-subvenciones-de-2024-para-lgmd-el-programa"/>
  <lastmod>2024-09-30T14:10:36+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-60</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-60"/>
  <lastmod>2024-09-30T21:31:01+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2024-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-third-quarter-2024-financial-results"/>
  <lastmod>2024-10-23T14:10:33+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-61</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-61"/>
  <lastmod>2024-10-31T21:30:35+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2024-financial-results-and-recent-corporate</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-third-quarter-2024-financial-results-and-recent-corporate"/>
  <lastmod>2024-11-06T21:32:03+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-global-licensing-and-collaboration-agreement-arrowhead</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-global-licensing-and-collaboration-agreement-arrowhead"/>
  <lastmod>2024-11-26T14:05:11+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-results-part-2-embark-study-demonstrating-sustained-benefits-and</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-results-part-2-embark-study-demonstrating-sustained-benefits-and"/>
  <lastmod>2025-01-28T16:15:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-revenue</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-revenue"/>
  <lastmod>2025-01-28T16:15:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-present-43rd-annual-jp-morgan-healthcare-conference</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-present-43rd-annual-jp-morgan-healthcare-conference"/>
  <lastmod>2025-01-28T16:15:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-62</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-62"/>
  <lastmod>2025-01-28T16:15:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-completes-enrollment-emergene-phase-3-clinical-study-srp-9003-treatment-limb</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-completes-enrollment-emergene-phase-3-clinical-study-srp-9003-treatment-limb"/>
  <lastmod>2025-01-28T16:15:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-63</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-63"/>
  <lastmod>2025-01-28T16:15:52+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2024-financial-results</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announce-fourth-quarter-and-full-year-2024-financial-results"/>
  <lastmod>2025-02-13T20:36:49+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-inaugural-600-million-senior-secured-revolving-credit-facility</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-inaugural-600-million-senior-secured-revolving-credit-facility"/>
  <lastmod>2025-02-15T04:00:05+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-recent</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-recent"/>
  <lastmod>2025-02-26T21:42:36+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-8th-annual-route-79-duchenne-scholarship-program</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-announces-call-applications-8th-annual-route-79-duchenne-scholarship-program"/>
  <lastmod>2025-03-01T04:00:46+00:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>http://www.sarepta.com/sarepta-therapeutics-anuncia-la-convocatoria-de-solicitudes-para-la-8a-edicion-anual-de-route-79-el</loc>
  <xhtml:link rel="alternate" hreflang="en" href="http://www.sarepta.com/sarepta-therapeutics-anuncia-la-convocatoria-de-solicitudes-para-la-8a-edicion-anual-de-route-79-el"/>
  <lastmod>2025-03-06T21:30:05+00:00</lastmod>
  <priority>0.5</priority>
 </url>
</urlset>
